|
|
 |
|
Viewing report
|
|
|
|
The Cancer Market Outlook to 2012
Business Insights, Jan 2008, Pages: 263
Medicines in the cancer therapeutic area account for the third largest source of revenue within the pharma industry. The cancer market has experienced significant innovative change in recent years, creating attractive opportunities for a range of new and established biotechnology players as well as established pharma companies. Although new product development continues to involve substantial levels of risk, innovation is the key driving force in the market, and has led to the competitive exclusion of several of the industry’s traditional competitors. With successful launches now being applied to multiple indications faster than ever before, subsequent increases in product sales volumes are rapidly changing the competitive landscape of the cancer market.
The Cancer Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market’s leading players are profiled. With coverage of over 9 % of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth.
Forecasts for currently marketed and key pipeline products over the 2 6-12 period are also provided. Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report.
Key Findings
-The cancer market expanded by 17.9% during 2006 and is forecast to reach $40.9b by 2012. The highest growth will occur in the antineoplastic class of drugs, which is expected to become the primary growth driver of the cancer market over the next four years.
- New launches such as Tykerb, Sutent and Nexavar will continue to drive rapid market growth due to their utility across multiple indications and specific side-effects profiles.
- The leading eight companies represented $17,927m (65.3%) of the of the global cancer market in 2006. AstraZeneca and Novartis are forecast to acheive the most rapid growth in their cancer portfolios over the forecast period, with modest gains expected for Amgen, Sanofi-Aventis and Lilly. Schering-Plough is forecast to register the
weakest performance of any major player.
- Major companies have begun to focus R&D activities upon the development of compounds with strong prospects across multiple indications, as efforts to create blockbuster products intensify. Future blockbusters are forecast to include AstraZeneca’s Zactima and Recentin as well as a Merck’s cervical cancer vaccine, Gardasil.
Top Five Reasons to Order Your Copy
-Assess patient potential, treatment trends and sales patterns across major cancer indications with this report’s detailed analysis of markets including Japan, France, Germany, Italy, Spain, the UK and the US.
- Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of Roche, Amgen, Sanofi-Aventis, AstraZeneca, Novartis, Pfizer, Schering-Plough and Lilly.
- Discover the market dynamics of the cancer area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting product development.
- Compare the future prospects of key players and forecast sales of leading products across major indications to 2012 with this report’s analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and trends in promotional spend for key brands.
- Identify the strategies that offer the greatest success potential within the future cancer market and understand the challenges currently facing companies within this therapeutic area.
Your Questions Answered
- Which indications will experience the greatest growth in the global cancer market over the period 2007-12?
- How have recent major product launches performed?
- What is the forecast market potential of the most exciting compounds currently in development for cancer indications?
- Which companies are best positioned for future success?
- What is the forecast market size and growth rate over the period 2007-2012 across the major cancer indications?
- How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
- Which pipeline products offer the highest growth potential?
- What will be the competitive landscape of leukaemia, lymphoma, lung, breast, pancreatic, colorectal, and prostate cancer in 2012?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Also available
The Cancer Market Outlook to 2011
Customers who bought this item also bought
The Cancer Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
The Cancer Market Outlook to 2010
The Cancer Market Outlook to 2011
Forecast Insight: Top 20 Cancer Therapy Brands
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
The Asian Cancer Market Outlook to 2010
The Cancer Market Outlook to 2009
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
Innovations in Cancer: Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
|
|
|
